209 related articles for article (PubMed ID: 10529691)
1. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
Knöbl P; Derfler K
Vox Sang; 1999; 77 Suppl 1():57-64. PubMed ID: 10529691
[TBL] [Abstract][Full Text] [Related]
2. Apheresis.
Nilsson IM; Freiburghaus C
Adv Exp Med Biol; 1995; 386():175-84. PubMed ID: 8851026
[TBL] [Abstract][Full Text] [Related]
3. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII.
Freedman J; Rand ML; Russell O; Davis C; Cheatley PL; Blanchette V; Garvey MB
Transfusion; 2003 Nov; 43(11):1508-13. PubMed ID: 14617307
[TBL] [Abstract][Full Text] [Related]
4. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).
Jansen M; Schmaldienst S; Banyai S; Quehenberger P; Pabinger I; Derfler K; Hörl WH; Knöbl P
Br J Haematol; 2001 Jan; 112(1):91-7. PubMed ID: 11167789
[TBL] [Abstract][Full Text] [Related]
5. Immunoadsorption of factor VIII inhibitors.
Freedman J; Garvey MB
Curr Opin Hematol; 2004 Sep; 11(5):327-33. PubMed ID: 15666656
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors.
Franchini M; Sassi M; Dell'Anna P; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Targher G; Lippi G
Semin Thromb Hemost; 2009 Feb; 35(1):76-80. PubMed ID: 19308895
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal adsorption of anti-factor VIII allo-antibodies on randomly functionalized polystyrene resins.
Huguet HC; Lasne D; Rothschild C; Siali R; Jozefonvicz J
Thromb Haemost; 2004 Feb; 91(2):259-66. PubMed ID: 14961152
[TBL] [Abstract][Full Text] [Related]
8. Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
Berntorp E
Haemophilia; 2006 Dec; 12 Suppl 6():62-5; discussion 65-6. PubMed ID: 17123396
[TBL] [Abstract][Full Text] [Related]
9. Management of factor VIII inhibitors: evolution and current status.
Bloom AL
Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
11. Management of hemophilia patients with inhibitors.
Hedner U; Glazer S
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
[TBL] [Abstract][Full Text] [Related]
12. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption.
Gjörstrup P; Berntorp E; Larsson L; Nilsson IM
Vox Sang; 1991; 61(4):244-50. PubMed ID: 1776241
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
[No Abstract] [Full Text] [Related]
14. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
15. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
[No Abstract] [Full Text] [Related]
16. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb).
Knöbl P; Derfler K; Korninger L; Kapiotis S; Jäger U; Maier-Dobersberger T; Hörl W; Lechner K; Pabinger I
Thromb Haemost; 1995 Oct; 74(4):1035-8. PubMed ID: 8560408
[TBL] [Abstract][Full Text] [Related]
17. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
[TBL] [Abstract][Full Text] [Related]
18. Use of Protein-A column and porcine factor VIII.
Rivard GE
Haemophilia; 2002 Jan; 8 Suppl 1():20-3; discussion 28-32. PubMed ID: 11882079
[TBL] [Abstract][Full Text] [Related]
19. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
Brakman GG
Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
[TBL] [Abstract][Full Text] [Related]
20. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.
Parry DH; Bloom AL
J Clin Pathol; 1978 Nov; 31(11):1102-5. PubMed ID: 739057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
